Literature DB >> 11118037

DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

I O Ng1, Z D Liang, L Cao, T K Lee.   

Abstract

We investigated the expression and deletion of DLC-1 (frequently deleted in liver cancer gene), first reported in 1998 and having a high homology with rat p122RhoGAP in hepatocellular carcinoma (HCC). Six (20%) of 30 human HCC samples and 2 (40%) of 5 HCC cell lines were found to have no detectable DLC-1 expression by reverse transcription-PCR. Homozygous DLC-1 deletion was detected by Southern blotting in two of six HCC samples and in both HCC cell lines with no DLC-1 expression. Transfection of DLC-1 into 5 HCC cell lines (two with DLC-1 deletion and three with intact DLC-1) showed significant growth inhibition in these two HCC cell lines with deleted DLC-1 with both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assays but not in three other HCC cell lines with intact DLC-1. Our findings suggest that DLC-1 may play an important role in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118037

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

Review 3.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

4.  Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation.

Authors:  Huina Liu; Huirong Shi; Yibin Hao; Guoqiang Zhao; Xiaofeng Yang; Yali Wang; Mei Li; Min Liu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

5.  Comprehensive analysis of long non-coding RNA PVT1 gene interaction regulatory network in hepatocellular carcinoma using gene microarray and bioinformatics.

Authors:  Yu Zhang; Yi-Wu Dang; Xiao Wang; Xia Yang; Rui Zhang; Zi-Li Lv; Gang Chen
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

6.  Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis.

Authors:  Tai On Yau; Thomas Ho Yin Leung; Sandra Lam; Oi Fung Cheung; Edmund Kwok Kwan Tung; Pek Lan Khong; Amy Lam; Sookja Chung; Irene Oi Lin Ng
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

7.  Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform.

Authors:  Mohammad G Sabbir; Nichola Wigle; Shauna Loewen; Yuan Gu; Cordula Buse; Geoffrey G Hicks; Michael R A Mowat
Journal:  BMC Biol       Date:  2010-03-03       Impact factor: 7.431

8.  StARD13(Dlc-2) RhoGap mediates ceramide activation of phosphatidylglycerolphosphate synthase and drug response in Chinese hamster ovary cells.

Authors:  Grant M Hatch; Yuan Gu; Fred Y Xu; Jeannick Cizeau; Shannon Neumann; Ji-Seon Park; Shauna Loewen; Michael R A Mowat
Journal:  Mol Biol Cell       Date:  2007-12-27       Impact factor: 4.138

9.  DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.

Authors:  Patrik Erlmann; Simone Schmid; Florian A Horenkamp; Matthias Geyer; Thomas G Pomorski; Monilola A Olayioye
Journal:  Mol Biol Cell       Date:  2009-08-26       Impact factor: 4.138

10.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.